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shis year’s 54th Annual Scientific Sessions of the American
ollege of Cardiology featured many exciting and original
ontributions. To the clinical cardiac electrophysiology sec-
ion alone, 512 abstracts were submitted, of which 181 were
ccepted for presentation. In addition, the results of several
mportant late breaking clinical trials were discussed. The
ollowing studies were presented at the Late Breaking
linical Trials Sessions and were considered as highlights.
he Optimal Pharmacological Therapy in Implantable
efibrillator Patients (OPTIC) trial, presented by Stuart
. Connolly for the OPTIC Investigators. The purpose
f the OPTIC trial (1) was to determine whether antiar-
hythmic therapy would reduce shocks (appropriate or not)
ompared to beta-blocker therapy alone. Patients were
onsidered eligible if they had either spontaneous ventricu-
ar tachycardia (VT) or left ventricular ejection fraction (EF)
40%, spontaneous ventricular fibrillation (VF), or induc-
ble VT or VF. A total of 412 patients were randomized to
hree groups: beta-blockers, amiodarone plus beta-blockers,
r sotalol. The investigators found that antiarrhythmic
herapy was more effective than beta-blockade alone (p 
.00006) and concluded that after implantable cardioverter-
efibrillator (ICD) implantation for spontaneous or induc-
ble VT or VF, the annual rate of shock is 30% even with
eta-blockers and optimal dual-chamber ICD program-
ing, and that amiodarone reduces shocks by 74%. “This
tudy shows shocks are very common in these patients, and
hat amiodarone is really effective in reducing their num-
er,” said Dr. Connolly. “The results represent a huge
eduction in shocks and a big improvement in quality of
ife.”
he Prospective, Randomized, and Controlled Study on
ffect of Catheter Ablation for the Cure of Atrial
ibrillation (CACAF) study, presented by Emmanuele
ertaglia for the CACAF Investigators. The CACAF
tudy (2) assessed the impact of antiarrhythmic therapy
ADT) alone, or therapy combined with both right and left
trial ablation, in preventing atrial fibrillation (AF) recur-
ence in patients with paroxysmal or persistent AF who have
lready failed ADT. A total of 137 patients were random-
zed to either ablation and ADT or ADT alone (controls).
ollow-up was for 12 months. Of the control group
atients, 94% versus 40.6% of the ablation group had at least
ne AF recurrence (p 0.001). The investigators concluded
hat ablation therapy, combined with ADT, was superior toa
From the Division of Cardiovascular Medicine, University of Florida, Gainesville,
lorida.DT alone in preventing atrial arrhythmia recurrences. “All
he patients in our study had a very long history of atrial
brillation,” said Dr. Bertaglia, Civic Hospital of Mirano,
nd Dr. Guiseppe Stabile, Casa di Cura S. Michele,
addaloni, Italy. “They had already failed at least two or
hree antiarrhythmic drugs. They are the most difficult
atients we encounter in clinical practice. Yet they re-
ponded after the execution of just one ablation procedure,”
rs. Bertaglia and Stabile agreed.
he Cardiac Resynchronization-Heart Failure (CARE-HF)
tudy, presented by John G. F. Cleland for the CARE-HF
nvestigators. The CARE-HF study (3) was an interna-
ional, randomized, unblinded parallel group trial that
valuated the effect of cardiac resynchronization therapy
CRT) on morbidity and mortality. Included were 813
atients followed for a mean of 29.4 months. Patients with
ew York Heart Association (NYHA) functional class III
nd IV heart failure owing to left ventricular systolic
ysfunction and cardiac dyssynchrony were randomized to
eceive either medical treatment alone or medical treatment
ith CRT. The primary end point was the time to death
rom any cause or any unplanned hospitalization for a major
ardiovascular event.
There were 82 deaths in the CRT group compared to
20 in the medical therapy group (p  0.002). The primary
nd point was reached by 159 patients in the cardiac
esynchronization group, as compared with 224 patients in
he medical therapy group (39% vs. 55%; p  0.001). The
nvestigators concluded that in patients with heart failure
nd cardiac dyssynchrony, CRT reduces the risk of death.
his benefit was seen as additive to standard pharmacologic
herapy. “We now have overwhelming evidence that
ardiac resynchronization therapy saves lives, slows the
rogression of heart failure, and improves symptoms and
orbidity in many heart failure patients; these results add
o previous study results demonstrating improvement in
eart failure symptoms and quality of life with CRT,” said
rofessor John G. F. Cleland, Chairman of the CARE-HF
teering Committee and head of the Department of Car-
iology, Castle Hill Hospital, Kingston-upon-Hull, United
ingdom.
he Chronicle Offers Management to Patients with
dvanced Signs and Symptoms of Heart Failure
COMPASS-HF) study, presented by Robert Bourge for
he COMPASS Investigators. The COMPASS-HF study
4) was a randomized, single-blind (patient), controlled trial of
pecialized heart failure (HF) care alone in a blocked clinician
ccess group (BCA) versus specialized HF care and clinical
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June 7, 2005:30B–2B ACC 2005 Annual Session Highlightsare guidelines using an implantable hemodynamic monitor
ystem (IHM, Chronicle, Medtronic Inc., Minneapolis, Min-
esota) in a total clinical access group (TCA). Patients enrolled
ad either NYHA functional class III or IV HF. Both systolic
nd diastolic HF patients were included.
Two hundred and seventy-four patients were randomized
ither to BCA (n  140) or TCA (n  134), and blinded
o that randomization for six months. Physicians were not
linded. All patients transmitted this IHM data weekly, and
tandard scripts were used during patient contact to main-
ain the blindness.
The primary safety end points of freedom from system-
elated complications and sensor lead failure were exceeded,
ith 0 lead sensor failures and 10% overall system
omplication rate. Overall, 25% fewer patients in the TCA
roup had an event when compared to the BCA group (74
s. 102 patients; p  0.27). Of note, the overall event rate
as significantly less than the hypothesized event rate (0.70
nd 0.89 in the TCA vs. BCA group, respectively, com-
ared to the 1.2 hypothesized), possibly explaining the lack
f statistical significance. Most of the events (84%) were HF
ospitalization. The TCA group had a 21% risk reduction
or this end point (p  0.029). Improvement was also seen
n the clinical composite score.
Interestingly, the effect of Chronicle-guided care was
een equally in patients with systolic and diastolic HF
egarding cumulative events. Another subgroup of note was
YHA class III patients. The TCA patients had a 41%
eduction (p  0.03) in cumulative events when compared
o those randomized to BCA.
The COMPASS-HF study demonstrates that the system
s safe and reliable, with benefit in those patients with both
ystolic and diastolic dysfunction. Dr. Bourge concluded
hat “A heart failure management strategy based on contin-
ously monitored intra-cardiac pressures in patients already
n the best available therapy and heart failure care directed
y expert heart failure clinicians significantly improved
atient morbidity.”
Many noteworthy abstracts were also presented in the
ral sessions. Of particular importance were several abstracts
eatured in a session entitled “Mapping and Ablation of
entricular Tachycardia.” Yarlagadda et al. (5) studied 29
atients referred for catheter ablation of repetitive mono-
orphic ventricular ectopy (RMVE) to determine the
ncidence of tachycardia-induced cardiomyopathy and to
ssess the impact of ablation on left ventricular (LV) func-
ion. Patients with normal and impaired (n  10) LV
unction were included. Ectopy was successfully ablated
rom within the right ventricular outflow tract (RVOT) in
5 (86%) patients, including 9 (90%) patients with impaired
V function. In the patients with impaired LV function,
even had follow-up assessment of LV function, with
emonstrated improvement. The investigators concluded
hat one-third of these patients had tachycardia-induced
ardiomyopathy, and that ablation may normalize EF.Next, Gonzalez et al. (6) studied 12 patients with Lrequent ICD shocks who underwent ablation of hemody-
amically unstable VT. They hypothesized that identifica-
ion of regions of slow conduction during sinus rhythm
ight facilitate catheter ablation of hemodynamically un-
table VT, and that these regions would show late potentials
LP) with activation times independent of the direction of
ctivation. The researchers concluded that the response to
ifferent directions of activation allowed identification of
P that might participate in re-entrant VT and that
blation of these potentials can eliminate unmappable VT.
Miljoen et al. (7) presented work describing three-
imensional (3D) electroanatomical mapping in 11 patients
ith arrhythmogenic right ventricular (RV) cardiomyopa-
hy/dysplasia and found that detailed 3D electroanatomical
apping was helpful in defining the VT mechanism and in
econstructing their circuits in patients with arrhythmogenic
V dysplasia.
Finally Jacobson et al. (8) investigated whether non-
ontact unipolar mapping can define arrhythmogenic sub-
trate and VT circuits. Using a pig model, myocardial
nfarction (MI) was induced in the left anterior descending
istribution. Dynamic substrate mapping was performed
nd found to be a reliable method to localize arrhythmo-
enic substrate in this model. Investigators suggested that
his technique might be useful for ablation of unmappable
T post-MI.
In a separately featured oral session, five abstracts were
resented addressing ablation of AF and modalities to aid in
voiding esophageal injury.
Cummings et al. (9) evaluated and compared different
odalities for determining anatomical variation and prox-
mity of the esophagus to the posterior wall of the left
trium. Fifty patients were imaged prior to pulmonary vein
ntrum isolation, and the closest distance between the left
trial (LA) endocardial surface and the esophageal lumen
as measured. They found significant variability in the
ocation of closest contact, with some close to the pulmo-
ary vein antral regions and 3 mm in distance. They
oncluded that integrating 3D-computed tomography scans
nto mapping systems might be a reliable tool in identifying
reas of increased risk for LA esophageal perforation.
Ren et al. (10) evaluated lesion morphologic and wall
hickness changes with radiofrequency (RF) delivered at the
A posterior wall-esophageal wall (LAPW-eso) using in-
racardiac echocardiography (ICE). A total of 42 patients
ndergoing LA pulmonary vein isolation were included.
he LAPW-eso wall thickness and changes in echogenic
esion thickness were measured under routine circumstances
nd during RF power titration using ICE monitoring.
hese investigators found that lesion changes may be
ontrolled and limited with power titration under ICE
esion monitoring. In a related abstract (11) the investiga-
ors demonstrated that the real-time ICE imaging of the
APW-eso region might provide an important tool to
onitor so as to avoid inadvertent esophageal injury during
A ablation.
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ACC 2005 Annual Session Highlights June 7, 2005:30B–2BLemola et al. (12) described the topographical anatomy of
he esophagus and the posterior LA using computed to-
ography (CT). Fifty patients underwent a spiral CT with
D reconstruction of the chest prior to an AF ablation
rocedure. The mean length and width dimensions of the
sophagus in contact with the posterior LA were 58  14
m and 13  6 mm, respectively. In 98% of patients, there
as a fat layer between the esophagus and the posterior LA.
he researchers found the esophagus had a variable course
ut was in close contact with the LA over a large area, often
ying within the ablation zone. They suggested that the layer
f adipose tissue may serve to insulate the esophagus from
hermal injury.
Finally, Cesario et al. (13) (presented by Charles Swerd-
ow) hypothesized that monitoring of esophageal tempera-
ure may detect early temperature rises to prevent esopha-
eal injury. They studied 12 patients using an esophageal
emperature probe positioned at the level of the 8-mm
blation tip. Maximum power and temperature were 40 to
0 W/50° to 55°. Ablation was terminated when there was
n abrupt rise in esophageal temperature (0.5°). Esopha-
eal temperature rose in 11 patients (92%), although they
ad no acute or chronic complications. The researchers
oncluded that esophageal temperature rises abruptly during
A catheter ablation at sites adjacent to the esophagus and
hat monitoring the esophageal temperature may reduce the
isk of LA-esophageal fistula.
An enormous amount of scientific information was pre-
ented at this year’s Scientific Sessions, making it impossible
o recognize the efforts of each investigator and the contri-
utions each one made to the success of the Clinical Cardiac
lectrophysiology Section. The aforementioned presenta-
ions were also formally offered at the “Highlights” sessions
n Wednesday, March 9, 2005.
eprint requests and correspondence: Dr. Jamie B. Conti,
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00277, Gainesville, Florida 32610-0277. E-mail: contijb@
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